STOCK TITAN
  1. Home
  2. Sec-filings
  3. RMD
  4. [Form 4] RESMED INC Insider Trading Activity

ResMed (RMD) insider Michael Farrell discloses RSU tax share sales

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ResMed Inc. (RMD) Chairman and CEO Michael Farrell, who is also a director, reported routine share dispositions related to tax withholding on restricted stock unit (RSU) vesting. On 11/11/2025, he disposed of 2,231.545, 3,459.325, and 2,205.697 shares of ResMed common stock back to the issuer at a price of $250.1 per share, each coded "F" to indicate they were withheld for taxes upon RSU vesting from grants dated 11/16/2022, 11/16/2023, and 11/16/2024. After these transactions, Farrell beneficially owned 459,969 ResMed shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.

Positive

  • None.

Negative

  • None.
Insider Farrell Michael J.
Role Chairman and CEO
Type Security Shares Price Value
Tax Withholding ResMed Common Stock 2,231.545 $250.10 $558K
Tax Withholding ResMed Common Stock 3,459.325 $250.10 $865K
Tax Withholding ResMed Common Stock 2,205.697 $250.10 $552K
holding ResMed Common Stock -- -- --
Holdings After Transaction: ResMed Common Stock — 465,634 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)
Footnotes (1)
  1. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2024.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Farrell Michael J.
(Last) (First) (Middle)
RESMED INC.
9001 SPECTRUM CENTER BLVD
(Street)
SAN DIEGO CA 92123
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman and CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
ResMed Common Stock 11/11/2025 F(1) 2,231.545 D $250.1 465,634 D
ResMed Common Stock 11/11/2025 F(2) 3,459.325 D $250.1 462,175 D
ResMed Common Stock 11/11/2025 F(3) 2,205.697 D $250.1 459,969 D
ResMed Common Stock 2,090 I Lisette and Michael Farrell Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022.
2. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023.
3. Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2024.
/s/ Mike J. Rider, attorney-in-fact for Mr. Farrell 11/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR